info@example.com

+1 66589 14556

BCG Therapy for Bladder Cancer

BCG Therapy for Bladder Cancer

📖 6 min read Written and medically reviewed by Dr. Alhad Naragude, MBBS, MS, DrNB Urology Last updated: September 6, 2026

BCG (Bacillus Calmette-Guérin) therapy is an intravesical immunotherapy used mainly for high-risk non-muscle-invasive bladder cancer, including carcinoma in situ (CIS) and many high-grade Ta/T1 tumours. The medicine is placed directly into the bladder through a catheter rather than given into a vein. It stimulates a local immune response against urothelial cancer cells. Treatment usually begins with an induction course of weekly instillations, followed by maintenance in appropriate patients. BCG is highly effective, but it does not work for every tumour and can cause urinary symptoms, fever and, rarely, serious systemic infection. High-grade recurrence after adequate BCG requires prompt reassessment rather than endless repeat courses.

Who is BCG used for?

  • Carcinoma in situ (CIS).
  • High-grade Ta bladder cancer with sufficient risk features.
  • High-grade T1 bladder cancer after adequate TURBT and usually repeat resection when indicated.
  • Selected intermediate-risk NMIBC depending on recurrence risk and alternatives.

BCG is not routinely needed for a single small low-grade Ta tumour.

How is BCG given?

  1. A small urinary catheter is inserted into the bladder.
  2. The bladder is drained.
  3. BCG solution is instilled through the catheter.
  4. The catheter is removed or clamped depending on protocol.
  5. You retain the treatment in the bladder for the prescribed period, usually around two hours if tolerated, then void according to the centre’s instructions.

Induction and maintenance

A standard induction course is commonly six weekly instillations. High-risk patients who respond may receive maintenance courses for one to three years depending on risk, guideline strategy, BCG availability and tolerability. Exact schedules can be modified if side effects or supply constraints occur.

Common side effects

Effect Typical pattern What to do
Frequency/urgency/burning Often begins within hours and settles over 1–2 days Hydrate as advised, use prescribed symptom relief and report persistent severe symptoms.
Small amount of blood in urine Can occur after catheterisation/BCG Monitor; heavy bleeding or clots need review.
Low-grade fever or malaise Mild flu-like symptoms may occur briefly Rest and monitor temperature; persistent/high fever needs urgent advice.
Severe systemic BCG infection Rare but serious High fever, rigors, breathing difficulty, hepatitis-like illness or sepsis symptoms require urgent hospital assessment.

When should BCG be postponed?

BCG is generally not given during a symptomatic urinary infection, significant visible haematuria, immediately after traumatic catheterisation, or too soon after a TURBT before the bladder lining has healed. The timing is individualized. Immunosuppression may also change suitability.

What does “BCG-unresponsive” mean?

BCG-unresponsive is a defined high-risk state where persistent or recurrent high-grade disease occurs after adequate BCG within specific time windows. In this setting, more BCG is unlikely to provide meaningful benefit. Radical cystectomy is the preferred oncological treatment for many fit patients; alternative intravesical or systemic therapies are considered when cystectomy is declined or unsuitable.

Why follow-up cystoscopy is still essential

BCG lowers risk but does not guarantee cure. Cystoscopy, urine cytology and sometimes biopsies are needed to confirm response and detect recurrence. CIS may be flat and difficult to see, so a suspicious cytology or mucosal change may require additional assessment.

Safety at home after BCG

Because BCG contains live attenuated mycobacteria, your centre will give specific instructions for toilet hygiene and handling urine for several hours after treatment. Follow those instructions exactly. Practices vary, so use the written protocol from your treating centre rather than internet dosing or disinfectant advice.

BCG failure needs precise language

A recurrence after one or two BCG instillations is not automatically “BCG-unresponsive.” Modern definitions consider whether the patient received an adequate course, whether the recurrence is papillary or carcinoma in situ, the grade, and when it occurred. The term BCG-unresponsive is important because further BCG is unlikely to provide adequate cancer control for that high-risk group.

For a surgically fit patient with BCG-unresponsive high-grade disease, radical cystectomy should be discussed as the reference curative option. Bladder-preserving alternatives and newer systemic/intravesical strategies can be appropriate when cystectomy is declined or unsuitable, but they should not be presented as equivalent without explaining the trade-offs.

What “adequate BCG” means in practical terms

BCG response cannot be judged fairly after a single instillation. Definitions of adequate BCG consider whether the patient received most of an induction course and, when indicated, additional maintenance or a second induction course. These details matter because the label BCG-unresponsive is reserved for high-grade disease recurring or persisting within defined time windows after adequate exposure.

If treatment was repeatedly interrupted by infection, traumatic catheterisation, severe toxicity or BCG shortage, the history should be reconstructed carefully before the disease is classified as treatment failure.

When to seek urgent medical care

After BCG, mild frequency, burning and low-grade flu-like symptoms can occur. High or persistent fever, shaking chills, breathlessness, marked weakness, confusion, jaundice or severe systemic illness needs urgent medical assessment because disseminated BCG infection, although uncommon, can be serious.

Consultation checklist

  • All TURBT pathology reports.
  • Dates and number of previous BCG instillations.
  • Record of interruptions or major BCG reactions.
  • Urine culture if recent urinary symptoms occurred.
  • Current immunosuppressive medicines or conditions.
  • Cystoscopy/cytology results after BCG.

FAQs

Is BCG chemotherapy?

No. It is an intravesical immunotherapy using attenuated Mycobacterium bovis to stimulate a local anti-tumour immune response.

Can BCG cause tuberculosis?

BCG is related to the organism used in the tuberculosis vaccine, but typical bladder symptoms are not tuberculosis. Rare systemic BCG infection can occur and requires urgent specialist treatment.

Should I continue BCG if I have severe burning?

Do not simply push through severe or persistent symptoms. The next dose may need postponement and urine testing or other assessment.

How soon after TURBT can BCG start?

It is usually delayed until the bladder lining has had time to heal; exact timing depends on resection and clinical status.

What if high-grade cancer returns after adequate BCG?

This may meet criteria for BCG-unresponsive disease. Radical cystectomy should be discussed promptly in fit patients, with alternative bladder-preserving options for those who decline or cannot undergo surgery.

If BCG causes side effects, does that mean it is working?

Not necessarily. Local urinary symptoms are common, but the severity of side effects does not reliably measure anticancer effect. Severe or systemic symptoms require medical assessment.

Related reading

References

Note: This information is for educational purposes only and is not a substitute for medical advice. Please consult your doctor for any symptoms.